ADC Therapeutics SA (ADCT)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ameet Mallik
Employees:
310
BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES, SWITZERLAND 1066
41 21 653 02 00

ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial.

Data derived from most recent annual or quarterly report
Market Cap 72.336 Million Shares Outstanding80.643 Million Avg 30-day Volume 325.464 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3
Price to Revenue1.4753 Debt to Equity1.3105 EBITDA-158.223 Million
Price to Book Value0.0 Operating Margin-58.8958 Enterprise Value1.076 Billion
Current Ratio4.507 EPS Growth0.337 Quick Ratio4.036
1 Yr BETA 0.8939 52-week High/Low 5.75 / 0.68 Profit Margin-74.223
Operating Cash Flow Growth-40.3835 Free Cash Flow to Firm (FCFF) TTM -176.709 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score-2.2548

Are you looking for this stock instead?

View SEC Filings from ADCT instead.

View recent insider trading info

ADC Therapeutics SA YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ADCT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADCT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FORET MICKEY P

  • Director
 20,000 2009-03-06 0

WUNSCH JOHN D

  • Director
 6,819 2008-03-18 0

MATHEWS JAMES G VP & CFO

  • Officer
 36,000 2007-04-30 0

GILLIGAN J KEVIN

  • Director
 5,646 2007-03-07 0

WANGBERG LARRY W

  • Director
 5,646 2007-03-07 0

SPIVEY WILLIAM

  • Director
 5,646 2007-03-07 0

BLANCHARD JOHN A III

  • Director
 5,646 2007-03-07 0

BOYLE JOHN J III

  • Director
 5,646 2007-03-07 0

MARTIN LOIS M

  • Director
 5,646 2007-03-07 0

REHFELD JOHN E

  • Director
 5,646 2007-03-07 0

HEMMADY GOKUL V VP & CFO

  • Officer
 21,220 2007-03-03 0

OWEN LAURA N VP HR

  • Officer
 20,194 2007-03-03 0

PFLAUM JEFFREY D VP & GENERAL COUNSEL

  • Officer
 17,133 2007-03-03 0

OBRIEN PATRICK D PRESIDENT CONNECTIVITY

  • Officer
 20,451 2007-03-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ADC THERAPEUTICS SA ADCT 2023-10-02 22:15:03 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 21:45:03 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 21:15:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 20:45:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 20:15:03 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 19:45:03 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 19:15:03 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 18:45:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 18:15:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 17:45:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 17:15:03 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 16:45:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 16:15:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 15:45:04 UTC 2.1908 3.1292 1100000
ADC THERAPEUTICS SA ADCT 2023-10-02 15:15:04 UTC 2.1908 3.1292 150000
ADC THERAPEUTICS SA ADCT 2023-10-02 14:45:03 UTC 2.5226 2.7974 150000
ADC THERAPEUTICS SA ADCT 2023-10-02 14:15:03 UTC 2.5226 2.7974 150000
ADC THERAPEUTICS SA ADCT 2023-10-02 13:45:04 UTC 2.2942 3.0258 150000
ADC THERAPEUTICS SA ADCT 2023-10-02 13:15:05 UTC 2.2942 3.0258 150000
ADC THERAPEUTICS SA ADCT 2023-10-02 12:45:05 UTC 2.2942 3.0258 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund ADCT -2368.0 shares, $-11413.76 2022-09-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ADCT -800.0 shares, $-1720.0 2023-06-30 N-PORT

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

WhaleWisdom Logo

Elevate your investments